Curriculum
Module 10 · 50 min

The Menopause Consultation: Equity, Risk Communication and Review

Structuring 15 minutes so the woman leaves with a plan, a number, and a date.

Endocrine & MHTCardiometabolicPrimary care track
Module progress0%
Quiz 0/3Cards 0/5Claims 0/6
Learning objectives

By the end of this module you will be able to

  • L01Run a structured menopause consultation covering symptoms, risk, options and review in a single visit.
  • L02State the SWAN findings on ethnic differences in VMS burden and duration.
  • L03Present absolute risk using natural frequencies and document the discussion defensibly.
  • L04Conduct an annual MHT review that covers efficacy, bleeding, BP, weight, and continuation rationale.
  • L05Recognise the referral triggers: POI, contraindications, refractory symptoms, unscheduled bleeding, complex oncology history.
Scope

Topics covered

01A repeatable consultation structure for a symptom-heavy presentation
02Ethnic and socioeconomic disparities in symptom burden and treatment access
03Risk communication: natural frequencies, icon arrays and documenting consent
04Occupational impact and workplace adjustments
05Annual review: what to actually check
06Handling misinformation, private clinic regimens and testosterone requests
07When to refer
Module narrative

How this plays out in practice

Primary care view· your track

Use a fixed spine for the consult: (1) symptoms and their impact, quantified; (2) stage and mimics excluded; (3) cardiovascular, bone and cancer-risk context; (4) options with absolute numbers; (5) the chosen plan written down; (6) a review date. Ask explicitly about genitourinary and sexual symptoms — they will not be volunteered. Book the 3-month titration review before she leaves.

Specialist view

Common referral patterns worth pre-empting: women arriving on private compounded regimens with supraphysiological levels, women on testosterone without a HSDD indication or monitoring, and women who were told to stop MHT at 5 years by a previous clinician. Each requires re-derivation of the indication rather than continuation by inertia. Unscheduled bleeding, POI, and a complex oncology history always warrant specialist involvement.

Advanced note

Disparity data are consistent across cohorts and are not explained by BMI or socioeconomic status alone; SWAN's analyses adjust for both. The equity failure is compounded downstream: women from minoritised groups are less likely to be offered MHT and more likely to have symptoms attributed to stress. Auditing your own prescribing by ethnicity and deprivation is a concrete, measurable quality improvement action.

Expected takeaways

What you should walk away believing

  • →In SWAN, Black women reported the longest total VMS duration (over 10 years) and Chinese and Japanese women the shortest — and treatment access runs in the opposite direction to need.
  • →There is no arbitrary stop date for MHT; continuation is a repeated shared decision, reviewed annually.
  • →Documenting a natural-frequency risk discussion protects the patient's autonomy and the clinician equally.
  • →Testosterone in women is licensed or supported only for hypoactive sexual desire disorder, at female physiological doses with level monitoring.
  • →Most 'treatment failure' is under-dosing, wrong route, wrong progestogen, or an unaddressed second diagnosis.
Myth-buster

What patients — and colleagues — get wrong

The claim

“MHT should be stopped after 5 years.”

Reality

No guideline supports an arbitrary stop date. The decision is a recurring shared one weighing ongoing symptoms, bone and cardiovascular context, and evolving risk. Many women continue safely beyond 5 years; some restart after an unsuccessful trial of stopping.

Graded claims

Evidence grading for this module

B

VMS duration and burden differ by ethnicity

Supported in defined populations — SWAN — longest in Black participants, shortest in Chinese and Japanese participants.

F

Arbitrary 5-year stop rules for MHT are evidence-based

Refuted or actively misleading — Explicitly rejected by NICE and the Menopause Society.

A

Natural frequencies improve risk comprehension over percentages

Established — RCT / guideline-grade — Robust risk-communication literature (Gigerenzer and colleagues).

B

Testosterone is supported for hypoactive sexual desire disorder in postmenopausal women

Supported in defined populations — Global Consensus Position Statement 2019.

D

Testosterone improves mood, energy or cognition in women

Biologically plausible, unproven — Not supported by the consensus statement; frequently marketed regardless.

B

Menopause symptoms measurably affect work participation

Supported in defined populations — Multiple national surveys and occupational cohort studies.

Evidence summary

Graded claims, key takeaways and sources for this module.

Open printable summary
Clinical vignettes

Apply it in clinic

Arriving on a private compounded regimen

A 49-year-old transfers to your list on compounded 'bioidentical' oestrogen and testosterone pellets prescribed privately, with salivary hormone monitoring. She feels well and wants NHS continuation.

Most appropriate response?

Self-assessment

Check your recall

Q1

Which group reported the longest total VMS duration in SWAN?

Q2

A woman has taken MHT for 6 years with good symptom control and no new risk factors. Correct advice?

Q3

The only indication with consensus support for testosterone in postmenopausal women is:

Flashcards

Retrieval practice

Card 1 / 5
Reviewed 0 / 5
Glossary

Terms used in this module

Natural frequency
Risk expressed as 'x in 1000 women over y years' — the format shown to maximise comprehension.
Hypoactive sexual desire disorderHSDD
Persistent, distressing loss of sexual desire — the only consensus-supported indication for testosterone in women.
Shared decision-making
An explicit process combining evidence on options with the patient's values, documented in the record.
Primary sources

Read the evidence yourself